Form 4: FATE CFO Adawi Receives Substantial Equity Awards

FATE THERAPEUTICS' Chief Financial Officer, Kamal Adawi, was granted 75,000 restricted stock units and options to purchase 375,000 shares of common stock.

Summary

• Kamal Adawi, Chief Financial Officer of FATE THERAPEUTICS INC, reported the acquisition of equity awards on October 20, 2025.
• The awards include 75,000 shares of Common Stock in the form of Restricted Stock Units (RSUs), acquired at a price of $0.00.
• These RSUs will vest in four equal annual installments, with the first vesting on November 1, 2026, and subsequent vestings on November 1, 2027, November 1, 2028, and November 1, 2029, subject to continued service.
• Additionally, 375,000 stock options were granted with an exercise price of $1.54 per share.
• The stock options will vest 25% on October 20, 2026, and thereafter on a monthly basis for 36 additional months, contingent on continuous service.
• The stock options have an expiration date of October 20, 2035.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The grant of equity awards to a key executive like the CFO is generally positive as it aligns management's interests with long-term shareholder value and aids in executive retention. While there's potential for future dilution, it's a standard and expected compensation practice that signals stability in leadership.

Positives

• Aligns management's interests with long-term shareholder value through significant equity ownership.
• Serves as a strong retention mechanism for a key executive, the Chief Financial Officer, ensuring continuity in leadership.
• The use of a Rule 10b5-1(c) plan indicates a pre-arranged, transparent compensation structure, reducing concerns about opportunistic insider trading.

Negatives

• Potential for future share dilution upon the vesting of RSUs and the exercise of stock options.
• The value of the awards is contingent on future stock performance, introducing market risk for the executive and potential volatility for shareholders.

Future Outlook

The equity awards are designed to incentivize long-term performance and retention of the Chief Financial Officer, aligning his financial interests with the company's future growth and shareholder value creation over the next several years, particularly through the multi-year vesting schedules.

Industry Context

The granting of equity awards, including restricted stock units and stock options, is a standard and widely adopted practice in the biotechnology and pharmaceutical industry to attract, retain, and motivate key executives. This compensation structure is common for companies like FATE THERAPEUTICS, which often have long development cycles and rely on long-term executive commitment to achieve strategic milestones and drive innovation.

Comparison to Industry Standards

• The structure of equity awards, combining RSUs and stock options with multi-year vesting schedules, is consistent with executive compensation packages observed across the biotechnology sector, including peers such as CRISPR Therapeutics (CRSP) or Editas Medicine (EDIT), which frequently use similar mechanisms to incentivize long-term performance.
• The size of the grant for a Chief Financial Officer at a company of FATE's market capitalization appears to be within typical ranges for executive compensation in the biotech industry, reflecting a balance between attracting talent and managing potential dilution.
• The exercise price of $1.54 for the stock options is likely based on the market price of FATE's common stock on the grant date, a common practice to ensure options are 'at-the-money' or 'in-the-money' at the time of grant, similar to practices at companies like bluebird bio (BLUE) or Sangamo Therapeutics (SGMO).

Corporate Governance

Stakeholder Impact

• **Shareholders:** Potential for long-term value creation through incentivized management performance; however, also potential for future share dilution upon vesting and exercise of awards.
• **Employees:** Signals stability in key executive leadership, potentially boosting morale and confidence in the company's direction and long-term strategy.
• **Management (Kamal Adawi):** Provides significant long-term incentive and compensation tied directly to the company's stock performance, fostering commitment and alignment.

Next Steps

• Continued service of Kamal Adawi with FATE THERAPEUTICS to meet vesting conditions for RSUs and stock options.
• Future vesting of 1/4th of RSUs annually on November 1st from 2026 to 2029.
• Future vesting of 25% of stock options on October 20, 2026, followed by monthly vesting for 36 additional months.
• Potential exercise of stock options by Kamal Adawi prior to the October 20, 2035 expiration date, subject to vesting and market conditions.

Key Dates

Recommendation

This Form 4 reports a routine equity award grant to a key executive, which is a standard compensation practice and does not typically provide a strong signal for a 'buy' or 'sell' recommendation. While it aligns management's interests with shareholders, the potential for future dilution is an expected aspect of such compensation. The filing itself does not contain new information that would fundamentally alter the investment thesis for FATE THERAPEUTICS, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

FATE THERAPEUTICS, FATE, Kamal Adawi, Chief Financial Officer, Form 4, Insider Transaction, Equity Award, Restricted Stock Units, Stock Options, Executive Compensation, Rule 10b5-1